When irregularities are found in a resident's drugs, to whom must the consultant pharmacist report?

When irregularities are found in a resident's drugs, to whom must the consultant pharmacist report?

• A. Attending physician and family
• B. Attending physician
• C. DON, Medical Director, and attending physician
• D. DON and Medical Director

Answer: (C)

When a consultant pharmacist finds irregularities in a resident’s drugs, the goal is to ensure immediate patient safety while getting appropriate medical and administrative oversight. The best practice is to report to three key leaders involved in the resident’s care: the attending physician who directly manages the patient’s therapy, the director of nursing who oversees medication administration and nursing processes, and the medical director who provides facility-wide clinical oversight and ensures alignment with policies and quality standards. Informing the attending physician allows prompt review and adjustment of orders, monitoring for adverse effects, and verifying that the medication plan is appropriate for the resident. Notifying the director of nursing ensures that any process or policy gaps are addressed, MARs and dispensing procedures are updated, and staff are informed to prevent recurrence. The medical director ties these actions to the facility’s overall clinical governance, reinforcing consistency with standard practices and regulatory expectations. Family involvement is not typically required for these internal medication issues, and omitting one of the three key leaders would leave gaps in patient-specific care, nursing operations, or overarching clinical governance.

When a consultant pharmacist finds irregularities in a resident’s drugs, the goal is to ensure immediate patient safety while getting appropriate medical and administrative oversight. The best practice is to report to three key leaders involved in the resident’s care: the attending physician who directly manages the patient’s therapy, the director of nursing who oversees medication administration and nursing processes, and the medical director who provides facility-wide clinical oversight and ensures alignment with policies and quality standards.

Informing the attending physician allows prompt review and adjustment of orders, monitoring for adverse effects, and verifying that the medication plan is appropriate for the resident. Notifying the director of nursing ensures that any process or policy gaps are addressed, MARs and dispensing procedures are updated, and staff are informed to prevent recurrence. The medical director ties these actions to the facility’s overall clinical governance, reinforcing consistency with standard practices and regulatory expectations.

Family involvement is not typically required for these internal medication issues, and omitting one of the three key leaders would leave gaps in patient-specific care, nursing operations, or overarching clinical governance.